Recombinant human erythropoietin (CHO Cell), Harbin Pharmaceutical Group Bioengineering

重组人促红素(CHO细胞) (哈药集团生物工程有限公司)

Report date: 2022/01/24 17:42:10

Base Information

Drug NameRecombinant human erythropoietin (CHO Cell), Harbin Pharmaceutical Group Bioengineering
Drug Alias Name雪达升
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsAnemia
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryMainland China
Original Approved Date2005/10/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A